China’s life sciences innovation is accelerating — but myths and misconceptions still cloud the outlook. From market variability to the rise of local competitors and shifting policy mandates, global stakeholders often struggle to see the full picture.
In this video briefing, L.E.K. Partner Helen Chen explains how government funding, biopharma R&D and institutional investment are driving renewed growth in China’s life-sciences enabler segment. She highlights where multinationals can still thrive — by focusing on customer segmentation and uncovering pockets of technology-driven demand.
Watch the full video to learn how to navigate the risks and unlock opportunities in this dynamic market
10142025231027